ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 Phase 1 Study With the Novel Bcl-2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Pts With CLL/SLL: Preliminary Data
By
ASH 2022 Conference Coverage
FEATURING
Chan Cheah
By
ASH 2022 Conference Coverage
FEATURING
Chan Cheah
37 views
December 22, 2022
Login to view comments.
Click here to Login
Leukemia